Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMOD for severe sepsis
ACTRN12607000376448Phase 2Not yet recruiting
- Sponsor
- Tehran University of Medical Sciences
- Start
- Aug 2007
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 2, randomised, open-label trial of IMOD in sepsis (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoint: All-cause mortality at 28 days. Planned start Aug 2007; status: not yet recruiting.
02
Drugs
IMOD
03
Conditions
sepsis
Beyond the preview
Go deeper on ACTRN12607000376448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000376448.